United States · Platforms & data · Investing.com

Oppenheimer reiterates Amgen stock rating on cancer drug data

Published by Investing.com · United States 2 h ago

Read the full article on Investing.com Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.investing.com)

Also worth reading

The Motley Fool

Vanguard S&P 500 ETF Long-Term Outlook: What Historical Trends Suggest for Patient Investors

Dr. Reddy's Laboratories Ltd (NYSE:RDY) Stock Has Consensus Target Price of $492.90

‘She’s living the dream’: My stepmother said I can buy my childhood home for $850,000. Is she taking advantage of me?

Samsung’s Galaxy Fit 4 could undercut Fitbit by $120

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

TeraWulf CEO Paul Prager Turns Elon Musk’s ‘Stranded Compute’ Warning Into A Buying Pitch